<DOC>
	<DOCNO>NCT01254578</DOCNO>
	<brief_summary>This phase I clinical trial study side effect best dose lenalidomide donor bone marrow transplant treat patient high-risk hematologic cancer . Biological therapy , lenalidomide , may stimulate immune system different way stop cancer cell grow .</brief_summary>
	<brief_title>Lenalidomide After Donor Bone Marrow Transplant Treating Patients With High-Risk Hematologic Cancers</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximal-tolerable dose ( MTD ) lenalidomide allogeneic hematopoietic stem cell transplantation ( AHSCT ) patient advance acute myeloid leukemia ( AML ) , non-Hodgkin 's lymphoma ( NHL ) , chronic lymphocytic leukemia ( CLL ) . II . Define qualitative quantitative toxicity lenalidomide regard organ specificity , time course , predictability , reversibility follow AHSCT patient . SECONDARY OBJECTIVES : I . Determine anti-tumor response patient treat lenalidomide AHSCT compare historical control . II . Evaluate plasma cellular pharmacokinetics lenalidomide patient enrol study interaction supportive agent calcineurin inhibitor . III . Evaluate frequency acute chronic graft-vs-host disease graft failure patient enrol study . IV . Prospectively assess feasibility administer oral agent post-transplant measure efficiency patient register therapy early also meet eligibility criterion lenalidomide treatment . V. Perform pharmacodynamic study follow lenalidomide treatment include development B , T , myeloid cell chimerism ; assessment immune activation ; cytokine ; tumor cell expression co-stimulatory molecule ; development anti-tumor antibody immunoglobulin recovery ; re-expression microRNAs may mediate lenalidomide anti-tumor effect . OUTLINE : This multicenter , dose-escalation study . Patients stratify accord diagnosis ( high-risk acute myeloid leukemia v non-Hodgkin lymphoma v high-risk chronic lymphocytic leukemia , small lymphocytic lymphoma , B-prolymphocytic leukemia ) . Patients receive oral lenalidomide daily day 1-28 . Courses repeat every 28 day 24 course absence disease progression unacceptable toxicity . Patients undergo blood bone marrow biopsy aspirate collection baseline periodically study pharmacokinetic pharmacodynamic study . Buccal swab sample also collect baseline analyze genetic polymorphism . After completion study therapy , patient follow 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Large Granular Lymphocytic</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Histologically confirm hematologic malignancy meet 1 follow criterion : Highrisk acute myeloid leukemia meeting 1 follow criterion : First complete response ( CR ) ≥ 60 year age OR &lt; 60 year age highrisk cytogenetics define CALGB OR highmolecular risk eligible willing undergo myeloablative conditioning Second later complete remission Not remission &lt; 5 % blast within 3 week start condition chemotherapy allogeneic transplantation Patients history CNS involvement allow provided disease remission time transplantation Patients nonHodgkin lymphoma candidate allogeneic stem cell transplantation eligible ; patient relapse status post autologous transplantation eligible long demonstrate chemotherapy sensitive disease ; patient history CNS involvement eligible aspect disease remission time transplantation Highrisk chronic lymphocytic leukemia ( CLL ) , small lymphocytic lymphoma ( SLL ) , primary secondary Bprolymphocytic leukemia ( PLL ) meet 1 follow criterion : del ( 17p13.1 ) disease treat ( may give consolidation therapy ) Less PR chemoimmunotherapy relapse within 2 year treatment Nucleoside analog refractory disease disease relapse two prior regimen Patients Richter ( large cell ) transformation allow provide large cell component disease remission ( &lt; 10 % large cell bone marrow allow ) Patient undergone allogeneic stem cell transplantation use reducedintensity nonmyeloablative conditioning regimen within past 60 day At least 40 % Tcell donor chimerism day 30 ECOG performance status 02 ( Karnofsky 60100 % ) Life expectancy &gt; 3 month Myeloid engraftment absolute neutrophil count &gt; 1,000/μL platelet count &gt; 50,000/μL ( allogeneic hematopoietic stem cell transplantation [ AHSCT ] ) Total bilirubin normal AST ALT ≤ 2.5 time upper limit normal ( ULN ) AST &lt; 3 time ULN AHSCT Creatinine clearance ≥ 50 mL/min stratum 1 ≥ 30 mL/min stratum 2 DLCO &gt; 40 % symptomatic pulmonary disease LVEF ≥ 30 % echocardiogram MUGA Not pregnant nursing Negative pregnancy test Fertile patient must agree use two acceptable method contraception ( one highly effective method one additional effective method ) practice abstinence ≥ 28 day , , ≥ 28 day complete lenalidomide HIV negative No uncontrolled infection require intravenous therapy poorly control diabetes mellitus No history allergic reaction attribute compound similar chemical biologic composition lenalidomide No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness and/or social situation would limit compliance study requirement No history grade 3 4 graftvshost disease ( GVHD ) If patient acute GVHD grade 1 2 , GVHD must control dose oral prednisone equivalent ≤ 20 mg per day ( AHSCT ) More 4 week since prior chemotherapy ( exclude steroid ) , radiotherapy , radioimmunoconjugate therapy ( 6 week nitrosoureas mitomycin C ) recover No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>